Try our beta test site

A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma

This study has been completed.
Information provided by (Responsible Party):
Can-Fite BioPharma Identifier:
First received: November 11, 2008
Last updated: February 26, 2015
Last verified: August 2014

November 11, 2008
February 26, 2015
February 2009
December 2012   (Final data collection date for primary outcome measure)
  • Dose Limiting Toxicity [ Time Frame: From start of treatment until Day 28 of Cycle 1 ]
    Dose-limiting toxicity was defined as a clinically significant AE or laboratory abnormality occurring in Cycle 1
  • Repeat-dose Pharmacokinetic Behavior of CF102 [ Time Frame: 1 month ]
  • Maximum Tolarated Dose [ Time Frame: first 28 days (Cycle 1) ]
    The MTD was defined as the highest dose level at which < 2 of 6 patients developed Cycle 1 DLT.
  • Dose limiting toxicity and maximum tolerated dose [ Time Frame: Continuous ]
  • Repeat-dose Pharmacokinetic Behavior of CF102 [ Time Frame: 1 month ]
Complete list of historical versions of study NCT00790218 on Archive Site
  • Therapeutic Effect of CF102 in Hepatocellular Carcinoma [ Time Frame: Every 2 months ]
  • Relationship Between Biomarkers of Peripheral Blood Mononuclear Cell (PBMC) Adenosine A3 Receptor (A3AR) Expression and Clinical Effects of CF102 [ Time Frame: Baseline ]
Same as current
Not Provided
Not Provided
A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma
A Phase 1-2, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered CF102 in Patients With Advanced Hepatocellular Carcinoma
This trial will test the safety and efficacy of CF102 in patients with advanced liver cancer. Successive groups of patients will be given higher doses of CF102 by mouth on a twice-daily basis. Treatment will be assessed for adverse effects and for effects on the tumor.
This is a multicenter, open-label, non-randomized, dose-escalation study, to be conducted in 2 phases: a dose-escalation phase, to determine the MTD of CF102 and to evaluate its safety/tolerability, PK, pharmacodynamic, and preliminary clinical activity; and a dose-confirmation phase, which will be a cohort expansion at or below the MTD (ie, the RP2D) of CF102. Subjects will be treated with oral doses of CF102 in consecutive, 28-day cycles. The initial dose of CF102 will be 1 mg twice daily (BID), with subsequent escalations to 5 and 25 mg BID, unless limited by toxicity. Subjects will be evaluated weekly for the first cycle, every 2 weeks for Cycles 2 and 3, and at the end of each subsequent cycle, up to 6 cycles of CF102 treatment. Subjects will return for a follow-up visit 28 days after completion of the last dose of study drug.
Phase 1
Phase 2
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Hepatocellular Carcinoma
Drug: CF102
CF102 capsules twice daily by mouth
Other Names:
  • 2-Chloro-N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide
  • Cl-IB-MECA
Experimental: CF102
An open-label trial (1, 5, and 25 mg BID) in 28-day cycles.
Intervention: Drug: CF102

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
December 2012
December 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Diagnosis of HCC:

    • For patients without underlying cirrhosis, diagnosis of HCC documented by cytology and/or histology
    • For patients with underlying cirrhosis, diagnosis of HCC established according to the American Association for the Study of Liver Diseases Practice Guideline algorithm (Appendix V).
  2. HCC is advanced, refractory, or metastatic, and no standard therapies are expected to be curative.
  3. At least 18 years of age.
  4. For subjects in the dose-confirmation (RP2D) phase only: Measurable disease, using Response Evaluation Criteria in Solid Tumors (RECIST, Appendix IV). (Note that a lesion that has been subjected to radiotherapy or chemoembolization cannot be used as a target lesion.)
  5. Eastern Collaborative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2 at baseline.
  6. The following laboratory values must be documented within 3 days prior to initiation of study drug:

    • Absolute neutrophil count (ANC) greater than or equal to 1 x 109/L
    • Platelet count greater than or equal to 50 x 109/L
    • Serum creatinine less than or equal to 2.0 mg/dL
    • Aspartic aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 × upper limit of normal.
    • Total bilirubin ≤ 3.0 mg/dL.
    • Serum albumin ≥ 3.0 g/dL.
    • International normalized ratio (INR) ≤ 2.3.
  7. Esophageal bleeding and varices, if present, have been sclerosed or banded, and no bleeding episodes have occurred during the prior 6 months.
  8. Life expectancy of ≥ 12 weeks.
  9. For women of childbearing potential, negative serum pregnancy test result.
  10. Absence of active malignancy other than HCC within 2 years of entry, with the exception of basal cell carcinoma and squamous cell carcinoma of the skin.
  11. Provide written informed consent to participate.
  12. Willing to comply with scheduled visits, treatment plans, laboratory assessments, and other study related procedures.

Exclusion Criteria:

  1. Any chemotherapy, immunomodulatory drug therapy, immunosuppressive therapy, corticosteroids > 20 mg/day prednisone or equivalent, or growth factor treatment (e.g., erythropoietin) within 14 days prior to initiation of study drug.
  2. Major surgery or radiation therapy within 28 days prior to initiation of study drug.
  3. Severe liver dysfunction (Child-Pugh Class C or hepatic encephalopathy).
  4. Active infection requiring systemic therapy.
  5. Uncontrolled congestive heart failure (New York Heart Association Classification 3 or 4), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, transient ischemic attack, or pulmonary embolism within 3 months prior to initiation of study drug.
  6. History of or ongoing cardiac dysrhythmias requiring treatment, atrial fibrillation of any grade, or persistent prolongation of the QTc (Fridericia) interval to > 450 msec for males or > 470 msec for females.
  7. Pregnant or lactating female.
  8. Women of childbearing potential, unless they agree to use dual contraceptive methods which, in the opinion of the Principal Investigator (PI), are effective and adequate for that patient's circumstances while on study drug.
  9. Men who partner with a woman of childbearing potential, unless they agree to use effective, dual contraceptive methods (i.e., a condom, with female partner using oral, injectable, or barrier method) while on study drug.
  10. Known human immunodeficiency virus- or acquired immunodeficiency syndrome-related illness.
  11. Any severe, acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, may interfere with the informed consent process and/or with compliance with the requirements of the study, or may interfere with the interpretation of study results and, in the investigator's opinion, would make the patient inappropriate for entry into this study.

Sexes Eligible for Study: All
18 Years to 80 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Can-Fite BioPharma
Can-Fite BioPharma
Not Provided
Study Director: Michael H Silverman, MD Can-Fite BioPharma Ltd
Principal Investigator: Salomon Shtemmer, MD Rabin Medical Center
Can-Fite BioPharma
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP